search results for 

Fresenius Biotech

Fresenius Biotech develops and commercializes innovative therapies with immunotherapeutic products. In 2012, two products were marketed: firstly, ATG-Fresenius S in transplantation medicine, and, secondly, the trifunctional antibody Removab for the treatment of cancer patients with malignant ascites.

In December 2012, Fresenius decided to focus on its four established business segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Biotech subsidiary will be discontinued. Fresenius is assessing the option of continuing the immunosuppressive drug ATG-Fresenius S, but will divest the trifunctional antibody Removab (catumaxomab) business.

Trifunctional Antibodies

Fresenius Biotech received the only Europe-wide approval to date for a monoclonal antibody developed in Germany when the European Commission approved Removab in 2009 for treating malignant ascites. The company subsequently obtained reimbursement approvals for Removab from the national health care systems of several European countries, providing the opportunity to expand marketing of the drug.

In 2012, sales of Removab were €4.1 million.

Immunosuppressive agent ATG-Fresenius S

With ATG-Fresenius S, a polyclonal antibody, Fresenius Biotech has a proven immunosuppressive agent that has been well established in the hospital market for decades, and is marketed in over 60 countries worldwide, being consistently profitable. ATG-Fresenius S is used for two therapeutic areas: it has been used for many years for organ transplant patients in order to avoid the rejection of transplanted organs. In addition, ATG-Fresenius S was granted approval in the prophylaxis of Graft-versus-Host-Disease (GvHD) in stem cell transplantation by German and Austrian authorities in 2011. ATGFresenius S was added to the list of reimbursable medications for stem cell transplantation in France in July 2012.

Sales of ATG-Fresenius S were €30.8 million in 2012.

Back to:
Fresenius Kabi
Continue reading: